Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

This decision is a blow for Eli Lilly and Novo Nordisk, who had both previously endorsed the proposed expansion.

Blood samples for sugar analysis were obtained whenever possible before and after the intramuscular administration of 1 mg. of crystalline glucagon. ¶ The patients' symptoms and their response to ...

Today CMS announced that payments to Medicare Advantage and Part D Prescription Plans would increase by 5.06% next year ...

Five scientists won this year’s Breakthrough Prize in Life Sciences for their work on GLP-1 and the development of drugs for ...

Gvoke VialDx has the potential to modernize the handling and administration of glucagon for diagnostic procedures," said Kevin McCulloch, President and COO of Xeris. "American Regent is the ...

Each Baqsimi device includes 1 dose of glucagon and cannot be refused. The Food and Drug Administration (FDA) has expanded the approval of Baqsimi (glucagon) nasal powder to include the treatment ...

Sen. Jim Banks (R-Ind.) wants the Food and Drug Administration to look into foreign-made active pharmaceutical ingredients he ...

In conclusion, the Glucagon-like Peptide-1 agonists market is poised for significant growth through 2034, driven by the ...